Skip to main content
. Author manuscript; available in PMC: 2015 Feb 1.
Published in final edited form as: Pharmacol Ther. 2013 Sep 27;141(2):140–149. doi: 10.1016/j.pharmthera.2013.09.005

Fig. 1.

Fig. 1

Notch signaling pathway and agents in clinical development. Two major classes of Notch inhibitors are currently in early clinical development: γ-secretase inhibitors (GSIs) and monoclonal antibodies (mAbs) against Notch receptors or ligands.